Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months

뉴스 본문을 불러오고 있어요.

Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months | 웨이프 WAPE

Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months

기사 요약

관련 종목

댓글 —